Dr. Rafael López López is an eminent figure in the field of Medical Oncology, leading national and international projects focused on the process of tumor dissemination.  

As head of the Medical Oncology Service of the University Hospital Complex of Santiago de Compostela, he has made possible, together with his team, the approval by the European Commission of the use of a new drug for the treatment of advanced breast cancer. This drug, palbociclib, has become not only the first kinase inhibitor approved in Europe, but also the first new first-line treatment approved for metastatic breast cancer in ten years. 

He balances his career as a medical specialist in oncology with research. He has published more than 100 clinical trials as lead researcher, including those related to solid tumors or the procedure of metastasis and liquid biopsy. 

• Head of the Medical Oncology Department at the University Hospital Complex of Santiago de Compostela
• Director of the Translational Medical Oncology Group at the Health Research Institute of Santiago de Compostela
• Creator of the Medical Oncology Service at the Txagorritxu Hospital. Vitoria, Spain
• Research Physician at the Oncology Department of the Free University Hospital. Amsterdam 
• Principal Investigator of more than 100 clinical trials, with emphasis in the field of Translational Research in Solid Tumors
• Author of more than 200 articles in prestigious national and international journals
• Founding Partner of the company Nasasbiotech
• Degree in Medicine from the Autonomous University of Madrid (UAM)
• Numerary member of the Royal Academy of Medicine and Surgery of Galicia
• Member of:
  
  • European Society for Medical Oncology (ESMO)
  • Spanish Society of Medical Oncology (SEOM)
  • American Society for Clinical Oncology (ASCO)
  • American Association for Cancer Research (AACR)